The Decentralised procedure used for the registration of ROVIs biosimilar of enoxaparin has been completed with positive outcome.


No votes yet
 
Related
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios...
2 min
16/02/2022
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) has announced that the European Commission has authorised the...
3 min
15/02/2022
  Madrid - January 28, 2022 Last May, ROVI signed a financing agreement with the Centre for Industrial Technological Development...
1 min
28/01/2022